Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.64 - $5.34
Previous CloseN/A
Volume1.63M
Average Volume (3M)11.59M
Market Cap
$1.55B
Enterprise Value$2.75B
Total Cash (Recent Filing)$10.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 26, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding604,501,040
10 Day Avg. Volume14,075,868
30 Day Avg. Volume11,586,441
Standard Deviation0.18
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)52.70
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-22.28
Enterprise Value/Ebitda-14.64
Forecast
1Y Price Target
$4.43Price Target Upside151.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceGERN reported preliminary 4Q24 Rytelo product revenue surpassing the Consensus estimate and demonstrating significant sequential growth.
Market PotentialRytelo is viewed as an important therapeutic option for RS negative MDS patients, given lack of alternatives.
Bears Say
Revenue Growth ConcernsA slower product launch is expected, leading to a decreased target price.
---
Ownership Overview
0.16% Insiders
12.98% Mutual Funds
33.63% Other Institutional Investors
39.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $1.55B.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Feb 26, 2025 which is 4 days ago.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Feb 26, 2025. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.015.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 604,501,040 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -32.068%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
---
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.43 (151.70% Upside)
$4.43 (151.70% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.74%
12-Months-Change
Fundamentals
Return on Equity
-66.09%
Trailing 12-Months
Asset Growth
50.68%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights significant achievements such as FDA approval and strong cash reserves, but also emphasizes challenges like flat revenue trends and the need for strategic adjustments. The sentiment is mixed, with both positive progress and areas needing improvement.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$4.43
▲(151.70% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Exelixis
―
Karyopharm Therapeutics
―
Sorrento Therapeutics
―
Best Analysts Covering GERN
1 Year
---